Animab raises €10 million for further development of edible antibodies

The proceedings will be used to bring its lead product to market and to expand the pipeline of antibody products in animal health

VIB spin-off Animab, which is developing a new class of orally administered antibodies for animal health, announced the successful closing of its Series A round. The proceedings will be used to bring its lead product to market and to expand the pipeline of antibody products in animal health. The investment round was led by the venture capital fund Qbic III with participation from existing investors among which V-Bio Ventures and VIB.

Animab builds on a proprietary and scalable platform technology, enabling efficient and cost-competitive generation of monoclonal antibodies for the prevention of intestinal infections in livestock. The orally administered antibodies are designed to improve the health, wellbeing, and performance of animals by controlling specific disease-causing pathogens.

Currently, the Animab lead product is a monoclonal antibody designed specifically against enterotoxigenic Escherichia coli (ETEC), the most important cause of post-weaning diarrhea in piglets globally. The company has demonstrated in vivo that the product prevents diarrhea and related clinical signs in ETEC infected piglets and will now further develop the product for regulatory approval. This product will also contribute to a more sustainable livestock production and significantly reduce antibiotic usage in animals.

Last year, Animab also received an €800,000 grant from the Flemish Agency for Innovation & Entrepreneurship (VLAIO) that supported the company in the research of the lead product. 

Alain Wille, CEO of Animab: “We appreciate the strong and continued support from our existing investors, who have enabled the company to progress to this point. We are proud to welcome Qbic as new investor, completing a strong investor syndicate. Overall, we are very excited with the progress we are making towards providing the production animal sector with an economically viable alternative for antimicrobials to control the most important pathogens.
Carla Snoeck, Manager New Ventures at VIB: “We are very excited about the significant progress made by Animab since its inception. This progress illustrates the efficacy of our tech transfer strategy and serves as a wonderful example of the positive impact that starting biotech companies can have on our society.”

Lies Vanneste

Lies Vanneste

Investor Relations Manager, VIB

Share

Latest stories

Website preview
Spectacular Breakthrough in Sepsis Research: Vitamin B1 Stops Deadly Lactate Production and Opens the Door to a New Treatment
Ghent, July 29, 2025 – Scientists in Ghent have achieved a major breakthrough in sepsis research. In a study on mice, the researchers demonstrate that vitamin B1 (thiamine pyrophosphate, TPP) restores mitochondrial energy metabolism, drastically reduces lactate production, and increases survival rates in sepsis. The study results were published in Cell Reports.
press.vib.be
Website preview
Scientists discover brain switch that controls freeze-or-flight survival instincts
Leuven, Belgium, 23 July 2025 – Researchers have identified a key neural switch that controls whether animals instinctively flee from a threat or freeze in place. By comparing two closely related deer-mouse species, they found that this switch is calibrated by evolution to match the animal's habitat. This neural circuit is hypersensitive in mice living in densely vegetated environments, causing instant escape, but less responsive in their open-field cousins, who are more likely to freeze. In doing so, the research team uncovered an important way in which evolution fine-tunes the brain for survival.
press.vib.be
Website preview
Groundbreaking Study Offers a Novel Approach to Enhance Neuromuscular Function in Patients with Duchenne Muscular Dystrophy
Findings published in The American Journal of Pathology identify GLUD1 enzyme as a potential therapeutic target for muscle restoration through metabolic reprogramming, addressing clinically unmet need for treatment beyond symptom relief
press.vib.be

About VIB

VIB is an independent research institute that translates insights in biology into impactful innovations for society. Collaborating with the five Flemish universities, it conducts research in plant biology, cancer, neuroscience, microbiology, inflammatory diseases, artificial intelligence and more. VIB connects science with entrepreneurship and stimulates the growth of the Flemish biotech ecosystem. The institute contributes to solutions for societal challenges such as new methods for diagnostics and treatments, as well as innovations for agriculture. 

Learn more at www.vib.be.

Contact

Suzanne Tassierstraat 1 9052 Zwijnaarde

+32 9 244 66 11

press@vib.be

vib.be